Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
3 participants
INTERVENTIONAL
2023-03-06
2023-07-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.
NCT06700057
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
NCT05570994
Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT07214961
68Ga-PSMA-11 PET/CT Screening Prior to 177Lu-PSMA-617 Therapy for Patients With Metastatic Castrate Resistant Prostate Cancer
NCT05547386
A Pilot Study of 123I-MIP-1072 SPECT/CT Imaging With Optional Compact Gamma Camera Probe Imaging in Men With Prostate Cancer Undergoing Prostatectomy
NCT01279785
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug
212Pb-NG001
212Pb-NG001
212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide.
Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
212Pb-NG001
212Pb-NG001 is a targeted alpha-emitting radiopharmaceutical conjugated to a PSMA targeting peptide.
Patients will receive an initial single 10 MBq dose IV to explore the imaging potential of 212Pb-NG001.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Life expectancy \>6 months
* Histological, pathological, and/or cytological confirmation of prostate cancer
* Metastatic castration resistant prostate cancer
* Failure of conventional treatment or such treatment not available/accepted by patient
* PSMA avid mCRPC lesions confirmed by PSMA PET/CT
* Adequate hematopoietic, kidney and liver function
Exclusion Criteria
* Concomitant diseases not compatible for radioactive therapy
* Previous PSMA-targeted radioligand therapy
* Concurrent serious (as determined by the Principal Investigator) medical conditions
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ARTBIO Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kjetil Berner, MD
Role: PRINCIPAL_INVESTIGATOR
Oslo University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Oslo University Hospital
Oslo, , Norway
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NG001-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.